Cost evaluation in head and neck cancer clinical trials: Implications for high-value care
‘American Journal of Otolaryngology', 2025
Head and neck cancer (HNC) patients face some of the highest financial burdens of all cancer types due to complex, long-term treatments. However, this study of over 2,000 HNC clinical trials found that only 3.3% included cost as an outcome, and nearly all have yet to report results. This is lower than in many other cancers, despite rising healthcare costs and the importance of cost-effective care. These findings highlight a need for more consistent inclusion of cost data in trials to better guide treatment decisions and support patients facing financial hardship.
Recommended citation: Collins RS, Lee IA, Habib DRS, Garner DC, Johnson DB, Patel PN, Topf MC. Cost evaluation in head and neck cancer clinical trials: Implications for high-value care. Am J Otolaryngol. 2025;46(5):104655. doi:10.1016/j.amjoto.2025.104655